Health

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance…

Published

4 years ago

June 18, 2021

Noosa Online News Publisher

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th…

Click here to view the original article.

Related Topics:Australia News-Medical.Net

Up Next

Alarming COVID study indicates long-term loss of gray matter and other brain tissue – News-Medical.Net

Don't Miss

Study finds that immune system protein may defend against deadly intestinal disease in babies – EdexLive

Business20 hours ago

Is Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?

General21 hours ago

Top chess player Magnus Carlsen forced into draw in historic game against over 134,000 people

General20 hours ago

Taiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts

Noosa News15 hours ago

Countdown on for Noosa Eat & Drink Festival 2025

Noosa Online News

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Trending